

## **Supporting Information**

### **Multiplexed Lipid Bilayers on Silica Microspheres for Analytical Screening Applications**

Nadiezda Fernandez Oropeza<sup>1</sup>, Nesia A. Zurek<sup>1\*</sup>, Mirella Galvan-De La Cruz<sup>1</sup>, Aurora Fabry-Wood<sup>1</sup>, Jennifer M. Fetzer<sup>1</sup>, Steven W. Graves<sup>1,2\*</sup>, Andrew P. Shreve<sup>1,2\*</sup>

<sup>1</sup>Center for Biomedical Engineering and <sup>2</sup>Department of Chemical and Biological Engineering  
University of New Mexico  
Albuquerque, NM 87131


\*Co-corresponding authors:

NAZ: email: nesia505@gmail.com; fax: (505) 277-1979


SWG: email: graves@unm.edu; fax: (505) 277-1979

APS: email: shreve@unm.edu; fax: (505) 277-1979


Supporting Figure S1: Time stability of individual and multiplex sets. The stability of the multiplexed sample over time is shown by comparison of individual and multiplexed samples.



Supporting Figure S2: Cholera toxin B subunit-Alexa 647 does not have specific interactions with the NBD-DOPE multiplex label. Bivariate plots of Cholera toxin B subunit B and NBD-DOPE indicate that no concentration-dependent interaction occurs between CTxB and the labeled lipid used for multiplexing.




Supporting Figure S3: Compensation details for biotin-streptavidin assays. Details of the compensation matrix applied to the biotin-streptavidin assay are presented.




**Figure S3.** Bivariate plots before and after compensation and compensation matrix used in the biotin-streptavidin assay. The left panel is a bivariate plot of FL-3 versus FL-1 signal intensity, and the right panel is the same data following application of compensation.

Supporting Figure S4: Interaction of Biotin-DOPE and Streptavidin-PE/Cy5 in the individual sample and multiplex approaches. Bivariate plots of streptavidin-biotin assay are shown for individual and multiplex samples.




**Figure S4.** Bivariate contour plots (compensated FL-3 vs. FL-1). Individual samples: **0 mol% Biotin:** **A)** Plus 0 nM SAV-Cy5. **B)** Plus 0.05 nM SAV-Cy5. **C)** Plus 0.25 nM SAV-Cy5. **D)** Plus 0.5 nM SAV-Cy5. **E)** Plus 2.5 nM SAV-Cy5. **0.05 mol% Biotin:** **F)** Plus 0 nM SAV-Cy5. **G)** Plus 0.05 nM SAV-Cy5. **H)** Plus 0.25 nM SAV-Cy5. **I)** Plus 0.5 nM SAV-Cy5. **J)** Plus 2.5 nM SAV-Cy5. **0.5 mol% Biotin:** **K)** Plus 0 nM SAV-Cy5. **L)** Plus 0.05 nM SAV-Cy5. **M)** Plus 0.25 nM SAV-Cy5. **N)** Plus 0.5 nM SAV-Cy5. **O)** Plus 2.5 nM SAV-Cy5. Multiplexed samples: **P)** Plus 0 nM SAV-Cy5. **Q)** Plus 0.05 nM SAV-Cy5. **R)** Plus 0.25 nM SAV-Cy5. **S)** Plus 0.5 nM SAV-Cy5. **T)** Plus 2.5 nM SAV-Cy5.

Supporting Figure S5: Streptavidin-PE/Cy5 does not have specific interactions with the NBD-DOPE multiplex label. Bivariate plots of Streptavidin-PE/Cy5 and NBD-DOPE indicate that no concentration-dependent interaction occurs between streptavidin and the labeled lipid used for multiplexing.



Supporting Figure S6: Compensation details for cross reactivity assays. Details of the compensation matrix as applied in the cross-reactivity assay are presented.



**Figure S6.** Bivariate plots before and after compensation and compensation matrix used in the cross-reactivity assay seen in: **A**) FL-3 versus FL-1 of the multiplex system with no added protein, before (left) and after (right) compensation. **B**) FL-4 versus FL-3 of the multiplex system plus SAv-Cy5, before (left) and after (right) compensation. **C**) Compensation matrix.

Supporting Figure S7: Cross-reactivity median fluorescence intensities – Median fluorescence intensities in FL-4 and FL-3 in cross-reactivity assay are presented.

